268 related articles for article (PubMed ID: 24917219)
21. HER2 expression and its clinicopathological features in resectable gastric cancer.
Kataoka Y; Okabe H; Yoshizawa A; Minamiguchi S; Yoshimura K; Haga H; Sakai Y
Gastric Cancer; 2013 Jan; 16(1):84-93. PubMed ID: 22410801
[TBL] [Abstract][Full Text] [Related]
22. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
[TBL] [Abstract][Full Text] [Related]
23. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
24. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
Stahl P; Seeschaaf C; Lebok P; Kutup A; Bockhorn M; Izbicki JR; Bokemeyer C; Simon R; Sauter G; Marx AH
BMC Gastroenterol; 2015 Feb; 15():7. PubMed ID: 25649416
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
[TBL] [Abstract][Full Text] [Related]
27. HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.
Huang SC; Ng KF; Lee SE; Chen KH; Yeh TS; Chen TC
Gastric Cancer; 2016 Jan; 19(1):176-82. PubMed ID: 25512144
[TBL] [Abstract][Full Text] [Related]
28. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
29. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma.
Nergiz D; Alikanoğlu AS; Süren D; Gömceli İ; Öztürk B
Indian J Pathol Microbiol; 2022; 65(2):321-327. PubMed ID: 35435366
[TBL] [Abstract][Full Text] [Related]
30. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
Cappellesso R; Fassan M; Hanspeter E; Bornschein J; d'Amore ES; Cuorvo LV; Mazzoleni G; Barbareschi M; Pizzi M; Guzzardo V; Malfertheiner P; Micev M; Guido M; Giacomelli L; Tsukanov VV; Zagonel V; Nitti D; Rugge M
Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
[TBL] [Abstract][Full Text] [Related]
31. Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer.
Zhang H; Wang Y; Wang Y; Wu D; Lin E; Xia Q
Pathol Res Pract; 2020 Nov; 216(11):153229. PubMed ID: 33010699
[TBL] [Abstract][Full Text] [Related]
32. Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology.
Tsapralis D; Panayiotides I; Peros G; Liakakos T; Karamitopoulou E
World J Gastroenterol; 2012 Jan; 18(2):150-5. PubMed ID: 22253521
[TBL] [Abstract][Full Text] [Related]
33. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer.
Ahn S; Hong M; Van Vrancken M; Lyou YJ; Kim ST; Park SH; Kang WK; Park YS; Jung SH; Woo M; Lee J; Kim KM
Mol Diagn Ther; 2016 Aug; 20(4):375-83. PubMed ID: 27179810
[TBL] [Abstract][Full Text] [Related]
34. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK).
Saito M; Yamashita K; Arimura Y; Kaneto H; Okuda H; Nojima M; Hagiwara T; Suzuki K; Adachi T; Goto A; Nakachi K; Yawata A; Yoshimoto M; Tanuma T; Adachi Y; Yamaoka S; Mizukoshi T; Kawayama M; Hamamoto Y; Shinomura Y
Acta Oncol; 2016; 55(3):309-17. PubMed ID: 26757197
[TBL] [Abstract][Full Text] [Related]
35. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance.
Sheng WQ; Huang D; Ying JM; Lu N; Wu HM; Liu YH; Liu JP; Bu H; Zhou XY; Du X
Ann Oncol; 2013 Sep; 24(9):2360-4. PubMed ID: 23788757
[TBL] [Abstract][Full Text] [Related]
36. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.
Fusco N; Rocco EG; Del Conte C; Pellegrini C; Bulfamante G; Di Nuovo F; Romagnoli S; Bosari S
Mod Pathol; 2013 Jun; 26(6):816-24. PubMed ID: 23348899
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
38. HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient.
Phan DAT; Nguyen VT; Hua TNH; Ngo QD; Doan TPT; Nguyen ST; Thai AT; Nguyen VT
J Pathol Transl Med; 2017 Jul; 51(4):396-402. PubMed ID: 28625044
[TBL] [Abstract][Full Text] [Related]
39. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
[TBL] [Abstract][Full Text] [Related]
40. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]